Robust humoral and cellular recall responses to AZD1222 attenuate breakthrough SARS-CoV-2 infection compared to unvaccinated

BACKGROUND: Breakthrough severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in coronavirus disease 2019 (COVID-19) vaccinees typically produces milder disease than infection in unvaccinated individuals. METHODS: To explore disease attenuation, we examined COVID-19 symptom burden...

Descripción completa

Detalles Bibliográficos
Autores principales: Maaske, Jill, Sproule, Stephanie, Falsey, Ann R., Sobieszczyk, Magdalena E., Luetkemeyer, Anne F., Paulsen, Grant C., Riddler, Sharon A., Robb, Merlin L., Rolle, Charlotte-Paige, Sha, Beverly E., Tong, Tina, Ahani, Bahar, Aksyuk, Anastasia A., Bansal, Himanshu, Egan, Timothy, Jepson, Brett, Padilla, Marcelino, Patel, Nirmeshkumar, Shoemaker, Kathryn, Stanley, Ann Marie, Swanson, Phillip A., Wilkins, Deidre, Villafana, Tonya, Green, Justin A., Kelly, Elizabeth J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9881590/
https://www.ncbi.nlm.nih.gov/pubmed/36713413
http://dx.doi.org/10.3389/fimmu.2022.1062067

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9881590/
https://www.ncbi.nlm.nih.gov/pubmed/36713413
http://dx.doi.org/10.3389/fimmu.2022.1062067

Ejemplares similares